Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Abstract Background Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also b...

Full description

Bibliographic Details
Main Authors: Samira Jeimy, Pari Basharat, Fiona Lovegrove
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Dermatomyositis
Omalizumab
Adverse drug reaction
Biologics
Online Access:http://link.springer.com/article/10.1186/s13223-019-0319-4

Internet

http://link.springer.com/article/10.1186/s13223-019-0319-4

Similar Items